Ideaya Biosciences Inc is trading at $31.99 (4.6%) up in pre-market, extending a multi-day rebound. - The surge follows continued positive sentiment after the company announced the first patient enrollment in a Phase 1 trial evaluating the combination of IDE892 and IDE397 for MTAP-deleted tumors. - Additionally, the company announced today the election of Yujiro S. Hata as Chairman of its Board of Directors, further boosting investor confidence.